In Japan, the agent is approved for the treatment of ATLL based on the results of a multicenter phase II study, which revealed the agent’s encouraging efficacy and tolerable side effects in patients with relapsed aggressive CCR4-positive ATLL. Here, CCR4 is linked to adult T-cell leukemia/lymphoma.